血清低氧诱导因子-1<i>α</i>、甲胎蛋白表达对肝癌患者肝动脉化疗栓塞术预后的影响

殷梦杰; 戴峰; 王斌; 王晓维; 沈建东; 丁苇; 付守忠

doi:10.7619/jcmp.20221712

血清低氧诱导因子-1α、甲胎蛋白表达对肝癌患者肝动脉化疗栓塞术预后的影响

Effect of expression of serum hypoxia inducible factor-1α and alpha fetoprotein on prognosis of transhepatic arterial chemoembolization in patients with liver cancer

摘要

摘要:
目的分析血清低氧诱导因子-1α(HIF-1α)、甲胎蛋白(AFP)表达对肝癌患者肝动脉化疗栓塞术(TACE)治疗预后的影响。
方法选取2019年1月—2021年12月行TACE治疗的80例肝癌患者作为研究对象, 3周为1个治疗周期，均治疗2个周期。患者均接受至少1个月随访，依据患者疾病缓解情况评估其预后，并分为不良组(n=34)与良好组(n=46)。比较2组基线资料，分析治疗前血清HIF-1α、AFP表达对肝癌患者TACE预后的影响。
结果随访1个月时，预后不良34例，占比42.50%。不良组血清AFP、HIF-1α水平高于良好组，差异有统计学意义(P < 0.05); 治疗前血清AFP、HIF-1α高表达可能是肝癌患者TACE治疗预后不良的风险因子(OR>1, P < 0.05); 受试者工作特征(ROC)曲线结果显示，治疗前血清AFP、HIF-1α水平预测肝癌患者TACE治疗预后不良风险的曲线下面积(AUC)均>0.70, 预测价值较为理想，且以联合预测价值最高。
结论肝癌患者治疗前血清AFP、HIF-1α的异常高表达对TACE治疗预后不良有一定的影响。

Abstract:
Objective To analyze the influence of the expression of serum hypoxia inducible factor-1α (HIF-1α) and alpha fetoprotein (AFP) on the prognosis of transhepatic arterial chemoembolization (TACE) in patients with liver cancer.
Methods A total of 80 patients with liver cancer treated by TACE from January 2019 to December 2021 were selected as research subjects, 3 weeks was a treatment cycle, all of them were treated for 2 cycles. All patients were followed up for at least 1 month, and their prognosis was evaluated according to their disease remission, and they were divided into poor group (n=34) and good group (n=46). The baseline data of the two groups were compared, and the effects of serum HIF-1α and AFP expression before treatment on the prognosis of liver cancer patients with TACE were analyzed.
Results At 1 month of followed up, 34 cases had poor prognosis, accounting for 42.50%; the levels of serum AFP and HIF-1α in the poor group were significantly higher than those in the good group (P < 0.05); high levels of serum AFP and HIF-1α before treatment might be risk factors for poor prognosis in patients with liver cancer after TACE treatment (OR>1, P < 0.05); the results of receiver operating characteristic (ROC) curve showed that the area under the curve (AUC) of serum AFP and HIF-1α levels before treatment in predicting the risk of poor prognosis in patients with liver cancer after TACE treatment were above 0.70, and the predictive value was ideal, and the combined predictive value was the highest.
Conclusion The abnormal high expression of serum AFP and HIF-1α in patients with liver cancer before treatment has a certain effect on the poor prognosis of TACE treatment.

HTML全文

参考文献(19)

施引文献

资源附件(0)